GO
Loading...

Dendreon Shares Take Off Ahead of FDA Panel Meeting

Shares of pharmaceutical firm Dendreon leaped on Wednesday following a CNBC report about a planned Thursday Food and Drug Administration hearing that could determine the fate of a prostate cancer drug from the company.

Dendreon seeks a positive recommendation for FDA approval of what would be the first-ever therapeutic cancer vaccine, reported CNBC pharmaceuticals reporter Mike Huckman. The drug, Provenge, has failed to meet some testing endpoints but also shows signs of conferring survival benefits.

The FDA usually follows the recommendations of panels such as the one meeting tomorrow -- but not all the time, Huckman said.

Dendreon shares , which are heavily shorted and have traded in a narrow range for the last 52 weeks, leaped after the CNBC report.

Prostate cancer is the second-most common cancer among U.S. men, killing about 30,000 annually.

Contact U.S. News

  • CNBC NEWSLETTERS

    Get the best of CNBC in your inbox

    › Learn More

Don't Miss

U.S. Video

  • Mad Money's Jim Cramer breaks down the theme of stealth technology stocks. Cramer says companies that are using proprietary technology to invent entirely new markets and then dominate those markets, fall under that category.

  • Mad Money host Jim Cramer knows it can be difficult to stick with a stock that is going lower but says if you've done the homework, and the story isn't wildly off the rails, then stay long.

  • Mad Money host Jim Cramer, outlines the most common emotionally driven investor mistakes and expresses why it is important to not let skepticism run away with you.